Abacavir-associated hypersensitive reaction: clinical case of severe course and modern view of the pathogenesis of the condition
М. A. Bulygin,
K. D. Kicherov,
V. D. Shamigulov,
D. V. Lavrenchuk,
K. V. Kozlov,
D. M. Shachmanov,
Yu. I. Bulan’kov,
А. А. Boiko,
Yu. I. Lyashenko https://doi.org/10.22328/2077-9828-2025-17-2-91-101
Abstract
The aim of the study is to describe a clinical case of severe abacavir-associated hypersensitive reaction — a specific side effect of antiretroviral therapy, manifested by various symptoms, requiring treatment in the intensive care unit — and to discuss possible pathogenetic mechanisms of hypersensitivity reaction development. The study methods were clinical observation of the patient and subsequent study of the medical history, as well as examination of scientific publications on the topic of the study. The features of this event are: failure to perform screening diagnostics of HLA-B*57:01 before modifying the antiretroviral therapy regimen — prescribing abacavir; patient’s lack of awareness of possible manifestations of hypersensitivity reaction and the procedure for detecting its symptoms; atypical clinical picture of the hypersensitivity reaction, expressed in the absence of the characteristic and most common exanthema syndrome.
About the Authors
М. A. Bulygin
Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
K. D. Kicherov
Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
V. D. Shamigulov
1472 Navy Clinical Hospital
Russian Federation
Russian Federation
Sevastopol
D. V. Lavrenchuk
Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
K. V. Kozlov
Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
D. M. Shachmanov
Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
Yu. I. Bulan’kov
Military Medical Academy; St. Petersburg Medico-Social Institute
Russian Federation
Russian Federation
St. Petersburg
А. А. Boiko
Military Unit 64994
Russian Federation
Russian Federation
Yu. I. Lyashenko
Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
References
1. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., Christiansen F.T. Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-transcriptase Inhibitor Abacavir // Lancet. 2002. Vol. 359. Iss 9308. P. 727–732. doi: 10.1016/s0140-6736(02)07873-x.
2. Mallal S., Phillips E., Carosi G., Molina J.M., Workman C., Tomazic J., Jagel-Guedes E., Rugina S., Kozyrev O., Cid J.F., Hay P., Nolan D., Hughes S., Hughes A., Ryan S., Fitch N., Thorborn D., Benbow A., PREDICT-1 Study Team. HLA-B*5701 Screening for Hypersensitivity to Abacavir // N. Engl. J. Med. 2008. Vol. 358. Iss. 6. P. 568–579. doi: 10.1056/NEJMoa0706135.
3. Araujo C., Carvalho C., Souza Freire M., Yamaguti A., Scaff I., Souza F., Silvestre Silva F., Diaz R., Guerreiro da Silva I. Prevalence of Human Leukocyte Antigen HLA-B*5701 in HIV-1 Infected Individuals in Brazil // Open Journal of Genetics. 2014. Iss. 4. P. 56–62. doi: 10.4236/ojgen.2014.41008.
4. Tumanov A.S., Laga V.Ju., Kazennova E.V., Kozyrev O.A., Sotnikov V.P., Kulagin V.V., Tonkikh O.S., Khafizov K.M., Urjanina N.I., Rakhmanova A.G., Potyomina L.P., Tsybakova O.A., Vdovina V.N., Olshansky A.Ya., Bobkova M.R. Voronin E.E. The Prevalence of HLA-B*5701 Allele in European Part of Russian Federation. Medical Genetics, 2010, Vol. 9, No. 8 (98), pp. 36–39 (In Russ.).
5. Schackman B.R., Scott C.A., Walensky R.P., Losina E., Freedberg K.A., Sax P.E. The Cost-effectiveness of HLA-B*5701 Genetic Screening to Guide Initial Antiretroviral Therapy for HIV // AIDS. 2008. Vol. 22. Iss. 15. P. 2025–2033. doi: 10.1097/QAD.0b013e3283103ce6.
6. Hetherington S., McGuirk S., Powell G., Cutrell A., Naderer O., Spreen B., Lafon S., Pearce G., Steel H. Hypersensitivity Reactions During Therapy with the Nucleoside Reverse Transcriptase Inhibitor Abacavir // Clinical Therapeutics. 2001. Vol. 23. Iss. 10. P. 1603–1614. doi: 10.1016/s0149-2918(01)80132-6.
7. Saag M., Balu R., Phillips E., Brachman P., Martorell C., Burman W., Stancil B., Mosteller M., Brothers C., Wannamaker P., Hughes A., Sutherland-Phillips D., Mallal S., Shaefer M. Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High Sensitivity of Human Leukocyte Antigen-b*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients // Clinical Infectious Diseases. 2008. Vol. 46. Iss. 7. P. 1111–1118. doi: 10.1086/529382.
8. Pathania V., Sinha A., Sood A., Kinra P., Das P., Sinha P., Shankar P. DRESS, the Maverick among SCARS: A Case Series-Based Review of Literature // Medical journal, Armed Forces India. 2023. Vol. 79. Iss. 3. P. 328–336. doi: 10.1016/j.mjafi.2020.11.027.
9. Yoon J.H., Kim M., Jin S.J., Kim S.K., Lee S.H., Cheon J., Yun G.Y., Kim M.K., Ha J., Song Y.G. The First Case of Abacavir Hypersensitivity Associated with the HLA-B*57:01-Positive Allele in Korea // Infection and Chemotherapy. 2012. Vol. 44. Iss. 5. P. 399–402. doi: 10.3947/ic.2012.44.5.399.
10. Koech M.K., Ali S.M., Karoney M.J., Kigen G. Severe Abacavir Hypersensitivity Reaction in a Patient with Human Immunodeficiency Virus Infection: a Case Report // Journal of Medical Case Reports. 2022. Iss. 16. Art. 407. doi: 10.1186/s13256-022-03647-6.
11. Illing P., Vivian J., Dudek N., Kostenko L., Chen Z., Bharadwaj M., Miles J.J., Kjer-Nielsen L., Gras S., Williamson N.A., Burrows S.R., Purcell A.W., Rossjohn J., McCluskey J. Immune Self-Reactivity Triggered by Drug-modified HLA-peptide Repertoire // Nature. 2012. Iss. 486. P. 554–558. doi: 10.1038/nature11147.
12. Norcross M.A., Luo S., Lu L., Boyne M.T., Gomarteli M., Rennels A.D., Woodcock J., Margulies D.H., McMurtrey C., Vernon S., Hildebrand W.H., Buchli R. Abacavir Induces Loading of Novel Self-peptides into HLA-B*57:01: An Autoimmune Model for HLA-associated Drug Hypersensitivity // AIDS. 2012. Vol. 26. Iss. 11. P. F21-F29. doi: 10.1097/QAD.0b013e328355fe8f.
13. Ostrov D.A., Grant B.J., Pompeu Y.A., Sidney J., Harndahl M., Southwood S., Oseroff C., Lu S., Jakoncic J., de Oliveira C.A., Yang L., Mei H., Shi L., Shabanowitz J., English A.M., Wriston A., Lucas A., Phillips E., Mallal S., Grey H.M., Sette A., Hunt D.F., Buus S., Peters B. Drug Hypersensitivity Caused by Alteration of the MHC-presented Self-Peptide Repertoire // Proceedings of the National Academy of Sciences. 2012. Vol. 109, Iss. 25. P. 9959–9964. doi: 10.1073/pnas.1207934109.
14. Voss S.D., Sondel P.M., Robb R.J. Characterization of the Interleukin 2 Receptors (IL-2R) Expressed on Human Natural Killer Cells Activated in Vivo by IL-2: Association of the p64 IL-2R Gamma Chain with the IL-2R Beta Chain in Functional Intermediate-Affinity IL-2R // Journal of Experimental Medicine. 1992. Vol. 176. Iss. 2. P. 531–541. doi: 10.1084/jem.176.2.531.
15. Trapani J. A., Smyth M. J. Functional Significance of the Perforin/Granzyme Cell Death Pathway // Nature reviews. Immunology. 2002. Vol. 2, No. 10. P. 735–747. doi: 10.1038/nri911.
16. Abelskaya I., Galitskaya S., Kachanka E., Kozachenko M., Trunova N., Melnikova V., Kononchuk S., Zhukovskaya O. Procalcitonin: Use as a Biomarker for Diagnosis and Indications for Antibiotic Therapy. A Literature Review. Cardiology in Belarus, 2022, Vol. 14, No. 5, pp. 632–641 (In Russ.). doi: 10.34883/PI.2022.14.5.009.
17. Simbirtsev A.S. Immunopathogenesis of and Prospects for Immunomodulatory Therapy for HIV Infection. Part 1. The General Aspects of Immunology and HIV. HIV Infection and Immunosuppressive Disorders, 2017, Vol. 9, No. 1, pp. 22–35 (In Russ.). doi: 10.22328/2077-9828-2017-9-1-22-3518.
18. Ipp H., Zemlin A.E., Erasmus R.T., Glashoff R.H. Role of Inflammation in HIV-1 Disease Progression and Prognosis // Critical reviews in clinical laboratory sciences. 2014. Vol. 51. Iss. 2. P. 98–111. doi: 10.3109/10408363.2013.865702.
19. Bonaci-Nikolic B., Jeremic I., Nikolic M., Andrejevic S., Lavadinovic L. High Procalcitonin in a Patient with Drug Hypersensitivity Syndrome // Internal Medicine. 2009. Vol. 48. Iss. 16. P. 1471–1474. doi: 10.2169/internalmedicine.48.2151.
20. Hubner S.T., Bertoli R., Ratz Bravo A.E., Schaueblin M., Haschke M., Scherer K., Ceschi A., Leuppi-Taegtmeyer A.B. C-Reactive Protein and Procalcitonin in Case Reports of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome // International Archives of Allergy and Immunology. 2018. Vol. 176. Iss. 1. P. 44–54. doi: 10.1159/000487670.
Review
For citations:
Bulygin М.A., Kicherov K.D., Shamigulov V.D., Lavrenchuk D.V., Kozlov K.V., Shachmanov D.M., Bulan’kov Yu.I., Boiko А.А., Lyashenko Yu.I. Abacavir-associated hypersensitive reaction: clinical case of severe course and modern view of the pathogenesis of the condition. HIV Infection and Immunosuppressive Disorders. 2025;17(2):91-101. (In Russ.) https://doi.org/10.22328/2077-9828-2025-17-2-91-101
Views:
34
.png)
Email this article 